354 related articles for article (PubMed ID: 27600664)
1. Differences in immune responses against Leishmania induced by infection and by immunization with killed parasite antigen: implications for vaccine discovery.
Mendonça SC
Parasit Vectors; 2016 Sep; 9(1):492. PubMed ID: 27600664
[TBL] [Abstract][Full Text] [Related]
2. Translating Observations From Leishmanization Into Non-Living Vaccines: The Potential of Dendritic Cell-Based Vaccination Strategies Against
Seyed N; Peters NC; Rafati S
Front Immunol; 2018; 9():1227. PubMed ID: 29922288
[TBL] [Abstract][Full Text] [Related]
3. Oral immunization using live Lactococcus lactis co-expressing LACK and IL-12 protects BALB/c mice against Leishmania major infection.
Hugentobler F; Di Roberto RB; Gillard J; Cousineau B
Vaccine; 2012 Aug; 30(39):5726-32. PubMed ID: 22814408
[TBL] [Abstract][Full Text] [Related]
4. Second-generation vaccines against leishmaniasis.
Coler RN; Reed SG
Trends Parasitol; 2005 May; 21(5):244-9. PubMed ID: 15837614
[TBL] [Abstract][Full Text] [Related]
5. Leishmania donovani p36(LACK) DNA vaccine is highly immunogenic but not protective against experimental visceral leishmaniasis.
Melby PC; Yang J; Zhao W; Perez LE; Cheng J
Infect Immun; 2001 Aug; 69(8):4719-25. PubMed ID: 11447143
[TBL] [Abstract][Full Text] [Related]
6. Vaccines in leishmaniasis: advances in the last five years.
Brodskyn C; de Oliveira CI; Barral A; Barral-Netto M
Expert Rev Vaccines; 2003 Oct; 2(5):705-17. PubMed ID: 14711330
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of the immunogenicity and protective efficacy of killed Leishmania donovani antigen along with different adjuvants against experimental visceral leishmaniasis.
Thakur A; Kaur H; Kaur S
Med Microbiol Immunol; 2015 Aug; 204(4):539-50. PubMed ID: 25432859
[TBL] [Abstract][Full Text] [Related]
8. Intradermal Immunization of Leishmania donovani Centrin Knock-Out Parasites in Combination with Salivary Protein LJM19 from Sand Fly Vector Induces a Durable Protective Immune Response in Hamsters.
Fiuza JA; Dey R; Davenport D; Abdeladhim M; Meneses C; Oliveira F; Kamhawi S; Valenzuela JG; Gannavaram S; Nakhasi HL
PLoS Negl Trop Dis; 2016 Jan; 10(1):e0004322. PubMed ID: 26752686
[TBL] [Abstract][Full Text] [Related]
9. Canine Leishmania vaccines: still a long way to go.
Gradoni L
Vet Parasitol; 2015 Feb; 208(1-2):94-100. PubMed ID: 25620293
[TBL] [Abstract][Full Text] [Related]
10. Testing of four Leishmania vaccine candidates in a mouse model of infection with Leishmania (Viannia) braziliensis, the main causative agent of cutaneous leishmaniasis in the New World.
Salay G; Dorta ML; Santos NM; Mortara RA; Brodskyn C; Oliveira CI; Barbiéri CL; Rodrigues MM
Clin Vaccine Immunol; 2007 Sep; 14(9):1173-81. PubMed ID: 17626159
[TBL] [Abstract][Full Text] [Related]
11. Genetically modified live attenuated parasites as vaccines for leishmaniasis.
Selvapandiyan A; Duncan R; Debrabant A; Lee N; Sreenivas G; Salotra P; Nakhasi HL
Indian J Med Res; 2006 Mar; 123(3):455-66. PubMed ID: 16778323
[TBL] [Abstract][Full Text] [Related]
12. Studies on the protective efficacy of freeze thawed promastigote antigen of Leishmania donovani along with various adjuvants against visceral leishmaniasis infection in mice.
Thakur A; Kaur H; Kaur S
Immunobiology; 2015 Sep; 220(9):1031-8. PubMed ID: 26001730
[TBL] [Abstract][Full Text] [Related]
13. Vaccine candidates for leishmaniasis: a review.
Nagill R; Kaur S
Int Immunopharmacol; 2011 Oct; 11(10):1464-88. PubMed ID: 21616175
[TBL] [Abstract][Full Text] [Related]
14. Leishmania donovani: identification of novel vaccine candidates using human reactive sera and cell lines.
Arora SK; Pal NS; Mujtaba S
Exp Parasitol; 2005 Mar; 109(3):163-70. PubMed ID: 15713447
[TBL] [Abstract][Full Text] [Related]
15. Transmission blocking vaccine studies in leishmaniasis: II. Effect of immunisation using Leishmania major derived 63 kilodalton glycoprotein, lipophosphoglycan and whole parasite antigens on the course of L. major infection in BALB/c mice.
Tonui WK; Mbati PA; Anjili CO; Orago AS; Turco SJ; Githure JI; Koech DK
East Afr Med J; 2001 Feb; 78(2):90-2. PubMed ID: 11682953
[TBL] [Abstract][Full Text] [Related]
16. Vector transmission of leishmania abrogates vaccine-induced protective immunity.
Peters NC; Kimblin N; Secundino N; Kamhawi S; Lawyer P; Sacks DL
PLoS Pathog; 2009 Jun; 5(6):e1000484. PubMed ID: 19543375
[TBL] [Abstract][Full Text] [Related]
17. Recombinant DNA-derived leishmania proteins: from the laboratory to the field.
Kubar J; Fragaki K
Lancet Infect Dis; 2005 Feb; 5(2):107-14. PubMed ID: 15680780
[TBL] [Abstract][Full Text] [Related]
18. Progress towards a Leishmania vaccine.
Tabbara KS
Saudi Med J; 2006 Jul; 27(7):942-50. PubMed ID: 16830009
[TBL] [Abstract][Full Text] [Related]
19. Antigenicity of a whole parasite vaccine as promising candidate against canine leishmaniasis.
Giunchetti RC; Reis AB; da Silveira-Lemos D; Martins-Filho OA; Corrêa-Oliveira R; Bethony J; Vale AM; da Silva Quetz J; Bueno LL; França-Silva JC; Nascimento E; Mayrink W; Fujiwara RT
Res Vet Sci; 2008 Aug; 85(1):106-12. PubMed ID: 17950391
[TBL] [Abstract][Full Text] [Related]
20. Challenges and perspectives in vaccination against leishmaniasis.
de Oliveira CI; Nascimento IP; Barral A; Soto M; Barral-Netto M
Parasitol Int; 2009 Dec; 58(4):319-24. PubMed ID: 19698801
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
